Brain Ischemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Brain ischemia may manifest as localized or widespread. Shock is one of the common systemic mechanisms that lead to global cerebral ischemia. Systemic hypotension is the most common cause of global cerebral ischemia. When autonomic and neurohormonal systems that regulate blood pressure and heart rate are compromised, as they are in postural tachycardia syndromes and vasovagal syncope, hypoperfusion can result. When an artery supplying a portion of the brain suddenly closes or significantly narrows, it can result in localized or multifocal cerebral ischemia. When hemodynamic dysfunction is the more immediate cause of a sharp drop in blood pressure, brain ischemia is often caused by a loss of blood supply to the entire brain. Usually, treating global brain ischemia aims to address the underlying cause. Supportive care should be implemented to guarantee sufficient cerebral blood flow; this can be achieved by keeping the patient flat or in the Trendelenburg position while further supportive measures are implemented. Assessing the patient's eligibility for acute reperfusion therapy is the first step in treating an acute ischemic stroke. For almost 25 years, intravenous thrombolytics have been used to treat acute ischemic stroke. As of right now, the only thrombolytic drug that the Food and Drug Administration has approved for the treatment of acute ischemic stroke, while tenecteplase efficacy research is ongoing. TPA has been approved for the treatment of acute ischemic stroke, provided it is given within three hours of the onset of symptoms; however, research suggests that giving TPA up to four hours after the onset of symptoms may still be safe and beneficial.
- In the US, the incidence rises with age; those over 65 account for roughly 75% of cases. Over the past 15 years, the prevalence of stroke has dropped in men, but it is almost the same in women, with a little female predominance.
Thelansis’s “Brain Ischemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Brain Ischemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Brain Ischemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Brain Ischemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment